Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $83.16 USD
Change Today +0.89 / 1.08%
Volume 356.8K
ESPR On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

esperion therapeutics inc (ESPR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $120.96
52 Week Low
07/18/14 - $13.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

esperion therapeutics inc (ESPR) Related Businessweek News

No Related Businessweek News Found

esperion therapeutics inc (ESPR) Details

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, as well as to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies. The company’s products also comprise 4WF, a synthetic apoA-I therapy for treating patients with acute coronary syndrome has completed Phase 2a clinical studies; and ESP41091, which is in pre-clinical trials for lipid metabolism and body weight reduction. Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.

21 Employees
Last Reported Date: 03/10/15

esperion therapeutics inc (ESPR) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $450.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $150.0K
Senior Advisor to Chief Executive Officer
Total Annual Compensation: $335.0K
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2014.

esperion therapeutics inc (ESPR) Key Developments

Esperion Therapeutics, Inc. Announces Management Appointments

Esperion Therapeutics, Inc. elected Scott Braunstein, M.D. to the Board of Directors of the company. Dr. Braunstein was elected as a Class III director and will serve until the company’s annual meeting of stockholders in 2016 or until his successor is duly elected and qualified, and was also appointed to serve on the company’s Audit Committee. Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management from 2014 through 2015. In addition, the company entered into an employment agreement with Mary P. McGowan, M.D. appointing Dr. McGowan as the company’s Chief Medical Officer, effective June 15, 2015. Dr. McGowan served as senior medical director of clinical development (cardiovascular) at Genzyme Corporation from 2012 to 2015.

Esperion Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:30 AM

Esperion Therapeutics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:30 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Keith F. Lenden, Vice President of Corporate Development & Strategy.

Esperion Therapeutics, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for 2015

Esperion Therapeutics, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $11,425,000 against $7,890,000 a year ago. Net loss was $11,466,000 or $0.56 per basic and diluted share against $7,874,000 or $0.51 per diluted share a year ago. The company expects that the net cash used to fund operating activities in 2015 will be approximately $42 million and that its cash and cash equivalents and investment securities will total approximately $290 million at December 31, 2015. The company estimates that current cash resources are sufficient to fund the company through 2018 and the expected approval of ETC-1002.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $83.16 USD +0.89

ESPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESPR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ESPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at